YOLFTbeta
Mesoblast Ltd

Mesoblast Ltd

MESO · NASDAQ · Healthcare / Biotechnology

13.27USD+0.17 (+1.30%)

Price History

Full chart

Market Stats

Previous Close13.10
Open13.13
Day Range12.89 – 13.28
52-Week Range11.89 – 21.50
Volume347.00K
Market Cap1.74B
P/E (TTM)0.00
Forward P/E454.55
EPS-0.44
Dividend Yield0.00%
Beta0.86
50-Day Avg15.00
200-Day Avg15.43

About

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Ryoncil for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
  • Employees108
  • Headquarters55 Collins Street, Melbourne, VIC, Australia, 3000, USA
  • Websitehttps://www.mesoblast.com

Leadership

  • Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director · b. 1957
  • Dr. Eric A. Rose M.D.Chief Medical Officer & Executive Director · b. 1951
  • Mr. Paul Hughes BPHARMGlobal Head of Corporate Communications & Joint Company Secretary
  • Mr. Anthony WhealHead of Human Resources
  • Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer · b. 1959
  • Ms. Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs & Quality Management
  • Mr. Daniel Devine B.Sc., J.D., M.B.AHead of Special Projects
  • Mr. Justin Horst B.S.Head of Manufacturing
  • Dr. Fiona See Ph.D.Senior VP & Head of Translational Research
  • Mr. Marcelo SantoroChief Commercial Officer

Financials

Income Statement

Currency: USD2005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue502.88K2.82M1.68M909.81K890.71K5.50K120.92M38.28M28.79M25.98M23.75M42.55M2.41M17.34M16.72M32.16M7.46M10.21M7.50M5.90M17.20M120.79M
Growth (%)-+461.11%-40.49%-45.82%-2.10%-99.38%+2198468.82%-68.34%-24.80%-9.75%-8.59%+79.16%-94.33%+618.95%-3.57%+92.30%-76.81%+36.95%-26.54%-21.32%+191.39%+602.33%
Cost of Revenue--------21.27M25.43M23.78M29.76M12.06M5.51M75.17M81.50M85.73M63.57M54.92M41.07M5.13M19.21M
Gross Profit502.88K2.82M1.68M909.81K890.71K5.50K120.92M38.28M7.52M546.00K-35.00K12.79M-9.65M11.83M-58.45M-49.34M-78.28M-53.36M-47.42M-35.17M12.07M101.58M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%26.12%2.10%-0.15%30.05%-400.21%68.24%-349.55%-153.44%-1049.83%-522.58%-632.20%-595.87%70.17%84.09%
Operating Expense1.49M9.11M8.69M8.85M10.32M10.39M27.16M87.00M67.60M72.92M113.36M68.67M80.39M89.17M21.75M25.53M30.82M27.21M21.87M48.98M74.51M153.08M
Operating Income-986.54K-6.28M-7.01M-7.94M-9.43M-10.39M93.76M-48.72M-60.08M-72.38M-113.39M-55.89M-90.04M-77.34M-80.20M-74.87M-109.10M-80.57M-69.29M-84.15M-62.44M-51.50M
Operating Margin-196.18%-222.70%-417.64%-872.67%-1058.60%-188851.78%77.54%-127.28%-208.71%-278.58%-477.48%-131.35%-3733.08%-445.99%-479.62%-232.84%-1463.20%-789.09%-923.73%-1425.74%-363.08%-42.64%
EBITDA-1.34M-8.14M-6.95M-7.78M-9.31M-10.97M92.44M-48.34M-59.31M-67.01M-90.19M-28.07M-87.16M-74.69M-84.53M-68.97M-84.65M-76.57M-58.55M-53.31M-73.66M-42.88M
EBITDA Margin-267.31%-288.65%-413.95%-855.44%-1045.14%-199515.44%76.44%-126.29%-206.02%-257.92%-379.79%-65.98%-3613.52%-430.71%-505.53%-214.49%-1135.35%-749.91%-780.56%-903.19%-428.30%-35.50%
Net Income-1.47M-8.30M-8.73M-10.06M-12.29M-14.78M90.61M-71.15M-61.66M-80.96M-119.37M-4.13M-76.81M-35.29M-89.80M-77.94M-98.81M-91.35M-81.89M-87.96M-102.14M-57.76M
Net Income Margin-292.39%-294.09%-519.74%-1105.99%-1379.29%-268743.55%74.93%-185.86%-214.21%-311.62%-502.64%-9.70%-3184.70%-203.51%-537.01%-242.38%-1325.25%-894.59%-1091.71%-1490.27%-593.92%-47.82%
R&D491.77K5.36M4.58M6.21M7.15M7.57M15.31M36.94M43.11M55.30M77.59M50.01M58.91M65.93M59.81M56.19M53.01M32.81M27.19M25.35M34.81M97.94M
R&D as % of Total Revenue97.79%189.89%273.01%682.27%802.24%137564.55%12.66%96.49%149.75%212.88%326.73%117.54%2442.54%380.18%357.70%174.74%711.00%321.37%362.47%429.57%202.39%81.09%
Interest Expense107.12K110.09K54200014.91K28904.33M10.53M9.31M01.83M11.70M14.72M10.71M17.29M19.44M20.66M22.93M23.95M
Interest Expense % of Total Revenue21.30%3.90%0.03%0.00%0.00%0.00%0.01%0.00%0.00%16.66%44.34%21.88%0.00%10.55%69.99%45.76%143.70%169.31%259.22%350.02%133.32%19.82%

Balance Sheet

Currency: USD2005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets21.47M16.38M21.24M27.79M26.98M39.51M763.25M720.46M883.71M899.31M1.02B684.02M655.69M692.44M652.12M733.60M744.72M662.14M669.41M669.15M784.68M773.08M
Total Liabilities2.20M4.42M698.90K1.57M1.19M1.60M247.41M241.61M253.45M327.60M408.57M155.86M138.92M146.44M171.06M184.28M163.32M165.10M167.58M188.80M187.24M204.67M
Total Equity19.26M11.97M20.54M26.22M25.79M37.92M515.84M478.85M630.27M571.72M609.36M528.16M516.77M546.01M481.05M549.33M581.40M497.04M501.84M480.36M597.44M568.40M
Cash15.09M7.85M12.06M14.09M16.53M32.05M263.23M206.75M7.88M3.83M27.51M21.86M45.76M37.76M50.43M129.33M136.88M60.03M70.92M62.56M161.16M47.39M
Total Debt-------------59.40M81.29M99.31M105.50M106.91M116.50M118.92M128.16M127.33M
Net Debt-15.09M-7.85M-12.06M-14.09M-16.53M-32.05M-263.23M-206.75M-7.88M-3.83M-27.51M-21.86M-45.76M21.63M30.86M-30.01M-31.39M46.87M45.58M56.36M-33.00M79.94M

Cash Flow

Currency: USD2005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-604.81K-3.18M-9.10M-6.20M-9.24M-9.66M108.23M-72.12M-54.08M-81.86M-121.71M-88.00M-95.47M-75.01M-57.79M-56.37M-106.68M-65.78M-63.27M-48.46M-49.95M-43.83M
Investing Cash Flow-4.97M-4.06M-3.38M-5.35M266.89K-343.45K4.71M5.33M-5.04M-40.81M-5.61M-1.73M142.00K-1.15M-1.00M-3.27M-1.65M-232.00K-194.00K-97.00K120.00K-1.02M
Financing Cash Flow20.67M-16.75M13.60M11.39M25.54M126.09M4.88M169.35M2.43M45.85M62.07M60.01M68.61M71.61M137.04M114.47M-9.87M74.50M40.25M147.34M-15.33M
Capital Expenditure752.61K153.48K181.85K100.96K170.02K87.11K461.55K2.71M2.84M37.92M2.72M922.00K311.00K201.00K279.00K2.25M1.65M232.00K314.00K331.00K730.00K898.00K
Free Cash Flow-1.36M-3.34M-9.28M-6.30M-9.41M-9.74M107.77M-74.82M-56.92M-119.78M-124.42M-88.92M-95.78M-75.21M-58.07M-58.61M-108.33M-66.01M-63.58M-48.79M-50.68M-44.73M
Dividends Paid---------------0000000
FCF to OCF224.44%104.82%102.00%101.63%101.84%100.90%99.57%103.75%105.25%146.32%102.23%101.05%100.33%100.27%100.48%103.98%101.54%100.35%100.50%100.68%101.46%102.05%
Dividend Paid to FCF---------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateFeb 12, 2015Aug 16, 2015Dec 16, 2015Feb 16, 2016May 9, 2016Aug 24, 2016Nov 14, 2016Feb 26, 2017May 24, 2017Aug 29, 2017Nov 14, 2017Feb 27, 2018May 30, 2018Aug 29, 2018Nov 15, 2018Feb 20, 2019May 30, 2019Aug 29, 2019Nov 25, 2019Feb 26, 2020May 27, 2020Aug 26, 2020Nov 19, 2020Feb 26, 2021Jun 2, 2021Aug 30, 2021Nov 23, 2021Feb 24, 2022May 31, 2022Aug 30, 2022Nov 22, 2022Feb 27, 2023May 25, 2023Aug 30, 2023Nov 22, 2023Feb 28, 2024Apr 30, 2024Jun 30, 2024Oct 30, 2024Feb 26, 2025May 30, 2025Aug 28, 2025Nov 26, 2025Dec 31, 2025May 29, 2026Jun 30, 2026
EPS Estimate-0.53-0.61--0.35-0.21-0.31-0.36-0.32-0.29-0.37-0.53-0.40-0.44-0.46-0.44-0.51-0.52-0.46-0.37-0.34-0.32-0.33-0.23-0.34-0.11-0.14-0.27-0.36-0.25-0.27-0.33-0.28-0.32-0.30-0.12-0.40-0.11-0.36-0.31-0.41-0.14-0.40-0.10-0.07-0.050.00
EPS Actual0.000.00-0.19-0.63-0.090.73-0.10-0.53-0.25-0.64-0.16-0.20-0.45-0.61-0.41-0.50-0.50-0.41-0.11-0.46-0.28-0.61-0.67-0.46-0.44-0.33-0.35-0.40-0.33-0.33-0.24-0.33-0.25-0.29-0.130.000.00--0.28-0.040.00-0.04-0.07-0.00-
Surprise100.00%100.00%--80.00%57.14%335.48%72.22%-65.63%13.79%-72.97%69.81%50.00%-2.27%-32.61%6.82%1.96%3.85%10.87%70.27%-35.29%12.50%-84.85%-191.30%-35.29%-300.00%-135.71%-29.63%-11.11%-32.00%-22.22%27.27%-17.86%21.88%3.33%-6.81%100.00%100.00%-9.68%90.24%100.00%90.00%30.00%-100.00%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hours-------

Key Statistics & Ratios

Market Cap1.74B
Enterprise Value1.77B
Trailing P/E0.00
Forward P/E454.55
PEG Ratio0.00
Price / Sales14.46
Price / Book3.01
EPS-0.44
Book Value4.38
Revenue (TTM)120.25M
Gross Profit (TTM)96.22M
EBITDA-44.60M
Profit Margin-47.82%
Operating Margin-33.28%
Return on Equity-9.86%
Return on Assets-4.11%
Shares Outstanding129.85M
Shares Float83.72M
Beta0.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 37.00
  • Strong Buy
    1
  • Buy
    2

Ownership Breakdown

Institutions
3.27%
Insiders
57.27%
Retail / Other
39.46%

Top Institutional Holders

  • Morgan Stanley - Brokerage Accounts
    718.61K0.55%
  • BlackRock Inc
    664.28K0.51%
  • Susquehanna International Group, LLP
    457.74K0.35%
  • The Goldman Sachs Group Inc
    395.61K0.30%
  • BNP Paribas Investment Partners SA
    259.70K0.20%
  • UBS Group AG
    200.05K0.15%
  • SRS Capital Advisors Inc
    168.02K0.13%
  • Bank of America Corp
    100.00K0.08%
  • Penbrook Management LLC
    87.08K0.07%
  • M&G PLC
    59.10K0.05%
  • Quadrature Capital Limited
    53.13K0.04%
  • LPL Financial Corp
    47.87K0.04%
  • Rialto Wealth Management, LLC
    46.50K0.04%
  • Royal Bank of Canada
    44.00K0.03%
  • Group One Trading, LLC
    44.03K0.03%
  • Two Sigma Investments LLC
    43.40K0.03%

Top Fund Holders

  • iShares Biotechnology ETF
    573.61K0.44%
  • UTM IM GBP AXA Framlington Biotech
    259.70K0.20%
  • M&G Recovery GBP A Acc
    59.10K0.05%
  • iShares Nasdaq US Biotech ETF USD Acc
    43.06K0.03%

Stock Splits

  • Jan 10, 20241:2